Clinical trial
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With…
NCT01532869 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT01532869 |
|---|---|
| Title | A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis |
| Official title | A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sclerosis, Systemic |
| Intervention type | Drug |
| Interventions | Placebo, tocilizumab [RoActemra/Actemra] |
| Enrollment | 87 |
| Start date | Mar 1, 2012 |
| Primary completion | Jan 1, 2014 |
| Completion | Aug 1, 2015 |
| First posted | Feb 15, 2012 |
| Last update posted | Sep 23, 2016 |
| Countries | Canada, France, Germany, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: